/PRNewswire/ XNK Therapeutics AB ("XNK") today announced that an abstract on the long-term follow-up of the Phase I/II clinical trial ACP-001 with its.
STOCKHOLM, June 10, 2022 /PRNewswire/ XNK Therapeutics AB ("XNK") today announced that an abstract on the long-term follow-up of the Phase I/II clinical trial ACP-001 with its leading candidate